Loading
A phase 1/2 trial of BA3071, Nivolumab, Pembrolizumab in melanoma, run by BioAtla, Inc., active and no longer recruiting.
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT05180799 by BioAtla, Inc., with 320 participants planned, started 2022-08-03 and due to reach its primary completion in 2025-03-19. Interventions recorded: BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta). Conditions listed: NSCLC, Melanoma. No results are recorded here; the registry entry is the source.
Shares Pemetrexed, Nivolumab, Pembrolizumab.
Shares Pemetrexed, Pembrolizumab.
Shares Pemetrexed, Melanoma, Pembrolizumab.
Shares Pemetrexed, Pembrolizumab.
Shares Pemetrexed, Nivolumab, Pembrolizumab.
Shares Pemetrexed, Nivolumab, Pembrolizumab.
Shares Pemetrexed, Nivolumab, Pembrolizumab.
Shares Pemetrexed, Nivolumab, Pembrolizumab.